Rein Therapeutics Inc. $RNTX Shares Bought by Voss Capital LP

Voss Capital LP boosted its stake in shares of Rein Therapeutics Inc. (NASDAQ:RNTX) by 59.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 4,243,969 shares of the company’s stock after purchasing an additional 1,577,437 shares during the quarter. Voss Capital LP owned about 0.16% of Rein Therapeutics worth $4,923,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RNTX. Susquehanna International Group LLP acquired a new stake in Rein Therapeutics during the 3rd quarter worth about $35,000. HRT Financial LP acquired a new stake in Rein Therapeutics during the 4th quarter worth about $38,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Rein Therapeutics during the 2nd quarter worth about $68,000. Jane Street Group LLC acquired a new stake in Rein Therapeutics during the 4th quarter worth about $72,000. Finally, Rock Creek Group LP acquired a new stake in Rein Therapeutics during the 4th quarter worth about $116,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on RNTX. Wall Street Zen raised Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. HC Wainwright dropped their target price on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.00.

Rein Therapeutics Stock Up 3.5%

NASDAQ:RNTX opened at $0.96 on Friday. Rein Therapeutics Inc. has a 52 week low of $0.89 and a 52 week high of $2.18. The stock has a market capitalization of $81.94 million, a PE ratio of -0.50 and a beta of 1.35. The stock’s 50-day moving average price is $1.27 and its 200-day moving average price is $1.28.

Rein Therapeutics (NASDAQ:RNTX) last posted its earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. Sell-side analysts expect that Rein Therapeutics Inc. will post -0.53 earnings per share for the current fiscal year.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.